Home/Filings/4/0000930413-17-002350
4//SEC Filing

Adamas Pharmaceuticals Inc 4

Accession 0000930413-17-002350

CIK 0001328143operating

Filed

Jun 20, 8:00 PM ET

Accepted

Jun 21, 8:48 PM ET

Size

14.3 KB

Accession

0000930413-17-002350

Insider Transaction Report

Form 4
Period: 2017-06-19
Transactions
  • Sale

    Common Stock

    2017-06-20$17.35/sh20,000$346,9342,231,351 total(indirect: Investment Mgr.)
  • Sale

    Common Stock

    2017-06-19$17.05/sh350,000$5,967,6752,251,351 total(indirect: Investment Mgr.)
  • Sale

    Common Stock

    2017-06-21$17.44/sh10,000$174,3652,216,351 total(indirect: Investment Mgr.)
JAY JEFFREY R
10% Owner
Transactions
  • Sale

    Common Stock

    2017-06-19$17.05/sh350,000$5,967,6752,251,351 total(indirect: Investment Mgr.)
  • Sale

    Common Stock

    2017-06-20$17.35/sh20,000$346,9342,231,351 total(indirect: Investment Mgr.)
  • Sale

    Common Stock

    2017-06-21$17.44/sh10,000$174,3652,216,351 total(indirect: Investment Mgr.)
KROIN DAVID
10% Owner
Transactions
  • Sale

    Common Stock

    2017-06-21$17.44/sh10,000$174,3652,216,351 total(indirect: Investment Mgr.)
  • Sale

    Common Stock

    2017-06-19$17.05/sh350,000$5,967,6752,251,351 total(indirect: Investment Mgr.)
  • Sale

    Common Stock

    2017-06-20$17.35/sh20,000$346,9342,231,351 total(indirect: Investment Mgr.)
Footnotes (7)
  • [F1]Consists of 94,851 shares owned by Biomedical Value Fund, L.P. ("BVF"), 145,713 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 103,098 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 6,338 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
  • [F2]Consists of 610,121 shares owned by Biomedical Value Fund, L.P. ("BVF"), 937,287 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 663,176 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,767 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
  • [F3]Great Point Partners, LLC ("Great Point") is the investment manager of each of BVF, BOVF, GEF-SMA and GEF-PS, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by each of them. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. David Kroin ("Mr. Kroin"), as special managing member of Great Point, has voting and investment power with respect to such shares, and therefore may be deemed to be the beneficial owner of such shares. Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.
  • [F4]Consists of 5,420 shares owned by Biomedical Value Fund, L.P. ("BVF"), 8,327 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 5,891 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 362 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
  • [F5]Consists of 604,701 shares owned by Biomedical Value Fund, L.P. ("BVF"), 928,960 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 657,285 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,405 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
  • [F6]Consists of 4,065 shares owned by Biomedical Value Fund, L.P. ("BVF"), 6,245 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 4,418 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 272 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").
  • [F7]Consists of 600,636 shares owned by Biomedical Value Fund, L.P. ("BVF"), 922,715 shares owned by Biomedical Offshore Value Fund, Ltd. ("BOVF"), 652,867 shares owned by GEF-SMA, L.P. ("GEF-SMA"), and 40,133 shares owned by Class D Series of GEF-PS, LP ("GEF-PS").

Documents

1 file

Issuer

Adamas Pharmaceuticals Inc

CIK 0001328143

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001328143

Filing Metadata

Form type
4
Filed
Jun 20, 8:00 PM ET
Accepted
Jun 21, 8:48 PM ET
Size
14.3 KB